Effect of angiotensin converting enzyme inhibition on the Doppler waveform in dogs with renal artery stenosis. 1999

R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
Department of Radiology, University of Rochester Medical Center, New York 14642, USA.

Our objective was to investigate whether the angiotensin converting enzyme inhibitor enalaprilat improves detection of hemodynamically significant renal artery stenoses in dogs. Renal artery stenoses of 50 to 99% were surgically created unilaterally in five dogs. Doppler ultrasonographic evaluation was performed at baseline (no stenosis), after creation of the stenosis, and after the administration of enalaprilat. The resistive index increased in the nonstenotic kidney (P < 0.01) but not in the stenotic kidney after administration of enalaprilat. The difference in resistive indices between nonstenotic and stenotic kidneys increased significantly (P < 0.05) after administration of enalaprilat. Measurement of the resistive index after administration of an angiotensin converting enzyme inhibitor in humans may improve the performance of Doppler ultrasonography in detecting hemodynamically significant renal artery stenoses.

UI MeSH Term Description Entries
D012078 Renal Artery Obstruction Narrowing or occlusion of the RENAL ARTERY or arteries. It is due usually to ATHEROSCLEROSIS; FIBROMUSCULAR DYSPLASIA; THROMBOSIS; EMBOLISM, or external pressure. The reduced renal perfusion can lead to renovascular hypertension (HYPERTENSION, RENOVASCULAR). Renal Artery Stenosis,Obstruction, Renal Artery,Obstructions, Renal Artery,Renal Artery Obstructions,Renal Artery Stenoses,Stenoses, Renal Artery,Stenosis, Renal Artery
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014655 Vascular Resistance The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT. Peripheral Resistance,Total Peripheral Resistance,Pulmonary Vascular Resistance,Systemic Vascular Resistance,Peripheral Resistance, Total,Resistance, Peripheral,Resistance, Pulmonary Vascular,Resistance, Systemic Vascular,Resistance, Total Peripheral,Resistance, Vascular,Vascular Resistance, Pulmonary,Vascular Resistance, Systemic
D015773 Enalaprilat The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion. Enalaprilic Acid,1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate,Enalaprilat Anhydrous,Enalaprilat Citrate, Anhydrous,Enalaprilat Dihydrate,Enalaprilat, (R)-Isomer, Anhydrous,MK-422,Pres iv,Vasotec,Xanef,MK 422,MK422
D018608 Ultrasonography, Doppler Ultrasonography applying the Doppler effect, with frequency-shifted ultrasound reflections produced by moving targets (usually red blood cells) in the bloodstream along the ultrasound axis in direct proportion to the velocity of movement of the targets, to determine both direction and velocity of blood flow. (Stedman, 25th ed) Doppler Ultrasonography,Doppler Ultrasound,Doppler Ultrasound Imaging,Doppler Ultrasound Imagings,Doppler Ultrasounds,Imaging, Doppler Ultrasound,Imagings, Doppler Ultrasound,Ultrasound Imaging, Doppler,Ultrasound Imagings, Doppler,Ultrasound, Doppler,Ultrasounds, Doppler

Related Publications

R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
September 1995, Radiology,
R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
May 1987, Kidney international. Supplement,
R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
May 1987, Kidney international. Supplement,
R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
September 1995, Academic radiology,
R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
March 1978, The New England journal of medicine,
R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
January 1992, American journal of nephrology,
R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
June 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
June 1989, Journal of human hypertension,
R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
June 1987, Angiology,
R H Gottlieb, and E Zusman, and D F Hartley, and D J Rubens, and S L Voci, and W Robinette, and L Melendez, and T W Morris, and S Ojha, and V Chengazi, and E Erturk, and E M Messing
December 2005, Seminars in interventional radiology,
Copied contents to your clipboard!